Skip to content

Group News

Stephen Saad raises funds for children’s hospitals

Apr 17, 2012

Durban: South African pharmaceutical social entrepreneur, Stephen Saad, has embarked on a personal initiative to help raise funds for paediatric healthcare facilities in South Africa. Stephen Saad said, “I fully embrace the social obligation to raise funds for the healthcare needs of underprivileged children and I’m calling on all organisations that have an interest in…

Read More >>

Aspen increases revenue by 31 percent

Mar 7, 2012

Johannesburg – JSE Ltd listed Aspen Pharmacare Holdings Limited (Apn), Africa’s largest pharmaceutical manufacturer, has announced pleasing results for the interim period ended 31 December 2011, once again proving Aspen’s resilience across its global businesses. Group Performance Revenue from continuing operations rose by 31 percent to R7.5 billion (R5.7 billion). Operating profit before amortisation from…

Read More >>

Aspen increases revenue by 29 percent to R12.4 billion

Sep 13, 2011

Johannesburg – JSE Ltd listed Aspen Pharmacare Holdings Limited, the leading pharmaceutical manufacturer in the southern hemisphere, has produced excellent results for the year ended 30 June 2011. GROUP PERFORMANCE: Revenue from continuing operations increased by 29% to R12.4 billion (R9,6 billion). Operating profit from continuing operations improved by 25% to R3.1 billion (R2.5 billion).…

Read More >>

Aspen increases revenue by 33 percent

Mar 3, 2011

Aspen increases revenue by 33 percent. Johannesburg – JSE Ltd listed Aspen Pharmacare Holdings Limited (Apn), Africa’s largest pharmaceutical manufacturer, has announced pleasing results for the interim period ended 31 December 2010. Group Performance: Headline earnings from continuing operations increased by 35 percent to R1.147 billion. Revenue from continuing operations rose by 33 percent to…

Read More >>

FM’s Nine Questions to Stephen Saad

Feb 24, 2011

Nine questions – Stephen Saad Group Chief Executive, Aspen Pharmacare Holdings Limited Xolile Bhengu Thursday, 24 Feb 2011 2011 started off with finalising the Sigma Pharmaceuticals deal for R6,1bn. What does the acquisition mean for Aspen? The Sigma acquisition presents synergies for the extension of our existing branded products in Australia, with the addition of…

Read More >>

Aspen granted generic license for the manufacture and supply of TMC278

Jan 27, 2011

Johannesburg. Aspen (APN), South Africa’s leading pharmaceutical company, has announced that Irish-based Tibotec Pharmaceuticals has granted it a non-exclusive license to manufacture, market and distribute the Anti-retroviral (“ARV”) compound, rilpivirine hydrochloride (TMC278), pending approval of the molecule which could then be prescribed for patients commencing ARV treatment for the first time as well as for…

Read More >>

Aspen acquires Sigma’s pharmaceutical business for R6,1 billion

Jan 14, 2011

Johannesburg. Aspen (APN), South Africa’s leading pharmaceutical company, has announced that all conditions precedent have been met for it to acquire the pharmaceutical business of Australian-based Sigma Pharmaceuticals Limited (“Sigma”). The acquisition was approved following the extraordinary meeting of Sigma shareholders held on 14 January 2011. The effective date of change of ownership is 31…

Read More >>

Aspen ARV tender bid is successful

Dec 14, 2010

Aspen ARV tender bid is successfulFollowing the announcement of the Anti-Retroviral (ARV) Tender results by the South African National Treasury Department, Aspen Pharmacare Holdings Limited is pleased to announce that its South African operating company (Aspen) has been successful in winning a number of key products in the tender, including Efavirenz and Tenofovir, in spite…

Read More >>

Aspen’s CSI programmes provide increased ARV access to mothers and infants

Nov 30, 2010

Aspen’s CSI programmes provide increased ARV access to mothers and infants Johannesburg. Aspen Pharmacare, South Africa’s leading pharmaceutical manufacturer, as part of its continued social commitment programme has established an antiretroviral (“ARV”) dispensary and has contributed to the upgrading of critical theatre equipment at the Rahima Moosa Mother and Child Hospital (“RMMCH”) in Coronationville. Stavros…

Read More >>

Aspen’s Revenue increases by 20% to exceed R10 billion

Sep 15, 2010

Johannesburg – JSE Ltd listed Aspen Pharmacare Holdings Limited, Africa’s largest pharmaceutical manufacturer, has produced excellent results for the year ended 30 June 2010. The South African business was the leading driver of the growth achieved. GROUP PERFORMANCE: Group revenue increased by 20% to R10.147 billion (R8.441 billion). Group operating profit improved by 20% to…

Read More >>

MEDIA ENQUIRIES

Shauneen Beukes
Group Communications Consultant
+27 31 580 8600
+27 82 389 8900
sbeukes@aspenpharma.com

Scroll To Top